On Dec. 4, the U.S. Food and Drug Administration announced that the 32 mg, single IV dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed. The dose has been associated with prolonged QT interval, which can lead to Torsades de Pointes, which can be fatal. Read more.
Single-dose IV Zofran pulled from market
Author(s):
Most Recent Content
For Nurse Practitioners
Do Vitamins, Plants Help Uterine Fibroid Risk or Treatment?
A research team out of Poland recently undertook a comprehensive examination of published data to determine the role that vitamins and diet might play...
